Keywords: Australia, TGA, Sanofi Pasteur, Panvax, H1N1, influenza, Side effects
654 suspected adverse reactions to Panvax reported to Australia’s TGA in one month
Article | 24 November 2009
The Australian national immunization program with the H1N1 2009 influenza vaccine Panvax, made by French drug major Sanofi-Aventis’ Sanofi-Pasteur unit, began on September 30, 2009, and the country’s Therapeutic Goods Administration has been closely monitoring any side effects from the use of the vaccine.
As at October 29, a total of 654 suspected side effects have been reported to the TGA following vaccination with Panvax in Australia, with over 3.75 million doses of the vaccine distributed in the country. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
